SB-121 is under clinical development by Scioto Biosciences and currently in Phase I for Autism Spectrum Disorder (ASD). According to GlobalData, Phase I drugs for Autism Spectrum Disorder (ASD) have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SB-121’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SB-121 overview
SB-121 is under development for the treatment of pervasive developmental disorder (PDD), childhood obesity, Clostridium difficile infections, necrotizing enterocolitis, sepsis, gut dysbiosis, neurology and metabolic disorders. The therapy is a biofilm of Lactobacillus reuteri, which is being developed based on activated bacterial therapeutics (ABT) delivery platform technology.
See Also:
Scioto Biosciences overview
Scioto Biosciences is a preclinical stage biotech company that focused on the activation of beneficial bacteria that have the potential to advance healing for various diseases associated with the GI tract, Oncology, and CNS indications. Scioto Biosciences is headquartered in Indianapolis, Indiana, the US.
For a complete picture of SB-121’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
